Merus Labs International Inc. Announces Promotion &

Merus Labs International Inc. Announces Promotion & Distribution
Agreements for Emselex(R)/Enablex(R) in European Countries 
TORONTO, ONTARIO -- (Marketwire) -- 01/17/13 -- Merus Labs
International Inc. ("Merus" or the "Company") (TSX:MSL)(NASDAQ:MSLI)
is pleased to announce that through its wholly owned subsidiaries,
Merus Labs B.V and Merus Labs Luxco S.a R.L., it has entered into
promotion and distribution agreements with selected partners in
certain European countries for the Company's Emselex(R)/Enablex(R)
product. Emselex(R)/Enablex(R) (darifenacin) is a branded
prescription medicine in extended release tablet form which is a
muscarinic antagonist indicated for the treatment of overactive
bladder with symptoms of urge urinary incontinence, urgency, and
frequency. 
The partner companies and corresponding territories are as follows;
POA Pharma Scandinavia AB (Nordic countries defined collectively as
Denmark, Norway, Sweden, Finland, and Iceland), Proximum d.o.o
(Croatia), and SPCare Lda (Portugal). Under the terms of the
agreements, the partner companies have been granted exclusive rights
to distribute, market, and sell Emselex(R)/Enablex(R) in their
respective territories. Although the financial terms of the
agreements have not been disclosed, the general structure of the
arrangements are such that the partners contribute the local
marketing and sales resources in exchange for a portion of the
incremental net sales generated above the current annual baseline net
sales. The territories covered by these new distribution and
promotion agreements did not have any substantial marketing and sales
resources devoted to the product in recent years. For the year 2012,
the newly partnered territories had net sales of approximately US$4.5
million. 
"We are pleased to have entered into these promotion and distribution
agreements with partner companies that have a wealth of knowledge and
expertise in their local markets. Emselex(R)/Enablex(R) is a major
growth driver for the Company and these new collaborations will
enable Merus to broaden its reach in countries which were previously
underserved in terms of marketing and sales efforts. This
announcement represents a key milestone within our strategic plan to
expand the sales of Emselex(R)/Enablex(R)", said Elie Farah, 
President and CEO of Merus Labs International Inc. 
About Merus Labs International Inc. 
Merus is a specialty pharmaceutical company engaged in the
acquisition and licensing of pharmaceutical products. The Company
utilizes its expertise in pharmaceutical markets and its access to
capital to acquire and license niche branded products. Merus further
enhances the sale and distribution of these products by the
introduction of a focused marketing and promotion plan. 
Cautionary Statement 
Certain statements contained in this press release may constitute
"forward-looking statements" within the meaning of Section 21E (i)
(1) of the United States Securities Exchange Act of 1934. Such
forward-looking statements involve known and unknown risks,
uncertainties and other factors that may cause Merus' actual results
to be materially different from any future results expressed or
implied by these statements. Such factors include the following:
general economic and business conditions, changes in demand for
Merus' products, changes in competition, the ability of Merus to
integrate acquisitions or complete future acquisitions, interest rate
fluctuations, currency exchange rate fluctuations, dependence upon
and availability of qualified personnel and changes in government
regulation. In light of these and other uncertainties, the
forward-looking statements included in this press release should not
be regarded as a representation by Merus that Merus' plans and
objectives will be achieved. These forward-looking statements speak
only as of the date of this press release, and we undertake no
obligation to update or revise the statements.
Contacts:
Merus Labs International Inc.
Elie Farah
President and CEO
(416) 593-3701
efarah@meruslabs.com